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Introduction: The potential advantages of oncoplastic breast conserving surgery (BCS) have not been
validated in robust studies that constitute high levels of evidence, despite oncoplastic techniques being
widely adopted around the globe. There is hence the need to define the precise role of oncoplastic BCS in
the treatment of early breast cancer, with consensual recommendations for clinical practice.
Methods: A panel of world-renowned breast specialists was convened to evaluate evidence, express
personal viewpoints and establish recommendations for the use of oncoplastic BCS as primary treatment
of unifocal early stage breast cancers using the GRADE approach.
Results: According to the results of the systematic review of literature, the panelists were asked to
comment on the recommendation for use of oncoplastic BCS for treatment of operable breast cancer that
is suitable for breast conserving surgery, with the GRADE approach. Based on the voting outcome, theom, nicolarocco2003@gmail.
ript.
Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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should be recommended versus standard breast conserving surgery for the treatment of operable breast
cancer in adult women who are suitable candidates for breast conserving surgery (with very low cer-
tainty of evidence).
Discussion: This review has revealed a low level of evidence for most of the important outcomes in
oncoplastic surgery with lack of any randomized data and absence of standard tools for evaluation of
clinical outcomes and especially patients’ values.
Despite areas of controversy, about one-third (36%) of panel members expressed a strong recommen-
dation in support of oncoplastic BCS. Presumably, this reflects a synthesis of views on the relative
complexity of these techniques, associated complications, impact on quality of life and costs.
© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
1.1. Breast cancer as a public health problem
Breast cancer is the most frequent malignancy among women,
with 2.1 million new cases diagnosed worldwide each year and the
leading cause of female death from cancer [1]. Although systemic
therapies have an increasingly prominent role in breast cancer
management, surgery remains the cornerstone of treatment for the
majority of early stage breast cancer patients. The equivalence of
outcomes between mastectomy and breast conserving therapy
(BCT) in terms of overall survival has been confirmed by long-term
follow up of seminal BCT trials [2,3]. Patients managed with BCT
have improved cosmetic outcomes and quality of life compared to
non-reconstructed mastectomy patients [4,5]. Nonetheless, breast
conservation surgery (BCS) does not always yield favorable results,
with 25e30% of women experiencing significant deformity
following surgery [6]. The percentage breast volume excision is a
crucial factor determining cosmetic outcome after completion of
both surgery and breast irradiation [7]. Techniques for oncoplastic
breast conserving surgery were developed with the aim of
improving cosmetic outcomes when compared with standard
breast conserving surgery [8,9], thus potentially resulting in better
quality-of-life. Moreover, oncoplastic surgery can reduce rates of
positive margins and need for re-excision or mastectomy due to
larger volumes of excised tissue [10]. Despite being widely adopted
around the globe, the potential advantages of oncoplastic surgery
have not been validated in robust studies that constitute high levels
of evidence [11]. There is hence the need to define the precise role
of oncoplastic BCS in the treatment of early breast cancer, with
consensual and unambiguous recommendations for clinical
practice.
1.2. Description of the target population
The primary target population for these guidelines are adult
womenwith either invasive or non-invasive operable breast cancer
undergoing BCS as primary treatment. These guidelines do not offer
information on surgical management of locally advanced breast
cancer following neoadjuvant chemotherapy and subsequent BCS,
nor on use of oncoplastic techniques for excision of multiple ipsi-
lateral cancers.
1.3. Aims and objectives of these guidelines
The purpose of these guidelines is to provide evidence-based
recommendations for use of oncoplastic BCS as primary treat-
ment of unifocal early stage breast cancers. The target audience
includes patients and a broad range of healthcare professionals
including: 1) breast surgical oncologists and plastic surgeons; 2)26radiation and medical oncologists; 3) breast radiologists; 4)
psycho-oncologists; 5) breast pathologists; 6) patients’ advocacy
representatives and 7) decision makers. Policy makers and other
stakeholders might express interest in these guidelines as use of
oncoplastic BCS can potentially impact on healthcare costs by
reducing rates of recurrence, and re-operations with enhanced
quality-of-life for patients.
The GRADE approach has been used to evaluate current evi-
dence and provide surgeons with actionable suggestions and allow
them to formulate recommendations [12].2. Methods
2.1. Panel composition and coordination
The panel was composed of twenty-one academics and clini-
cians from across the world with expertise in the field of breast
cancer management, and included breast surgical oncologists,
plastic surgeons, medical and radiation oncologists, dedicated
breast radiologists, pathologists, psycho-oncologists, breast care
nurses, patient advocacy representatives and patients themselves
(Supplemental file 1). The panelists were invited to participate in
face-to-face discussions during the Milan International Oncoplastic
Breast Surgery Meeting held in December 2019 [13]. The panel was
selected by a designated leading group (NR, GC, MBN, GM, RDM).
The panelists were recognized experts in their fields and were
chosen on the basis of semiquantitative selection criteria with
representation from Europe, Middle East, North and South Amer-
ica: familiarity with relevant specialties involved in the multidis-
ciplinary management of breast cancer; membership of
international organizations (St Gallen International Breast Cancer
Conference; San Antonio Breast Cancer Symposium; European So-
ciety of Surgical Oncology (ESSO)) [14e16]; authorship of peer-
reviewed papers on breast cancer multidisciplinary management
in high-impact factor journals; other specialists working in
comprehensive breast units with regular participation in multi-
disciplinary teammeetings. The panel chair and co-chair were both
breast surgical oncologists (NR and GC respectively). The leading
group comprised a panel chair and co-chair, the meeting president
(MBN) and two other breast surgical oncologists (GM and RDM)
with specific training in GRADE methodology.
The leading group of the consensus conference first met in May
2019 at Mario Negri Institute for Pharmacologic Research IRCCS in
Milan, where a course was organized by members of the working
group (IM and MC) to specifically train the leading group (NR, GC,
MBN, GM and RDM) who defined the main questions in the
guidelines, compiled a list of outcomes and chose panel members.
All panelists were asked to declare any conflicts of interest prior to
all meetings.
Using GRADEpro software [17] the proposed list of outcomes
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suggested appropriate changes. After integrating feedback from
panelists, the outcome list was modified accordingly and outcomes
then graded based on perceived importance (on a scale from 1 to 9:
1e3 low importance; 4e6 important but not critical for decision
making; 7e9 critical for decision making).
The draft version of the document was sent to external re-
viewers prior to the finalization. The external reviewers were
nominated by the Group for Reconstructive and Therapeutic Ad-
vancements (G.Re.T.A) [18] and other scientific bodies (European
Society of Surgical Oncology (ESSO) [16]).
The Mario Negri Institute for Pharmacological Research IRCCS
conducted the systematic review of evidence and coordinated the
process of guideline development applying the GRADE methodol-
ogy [12].
2.2. Guideline funding and management of conflicts of interest
Conflicts of interest for all participants were managed with
advice from the Institute of Medicine [19]. No conflicts of interest
were declared at each meeting by the chair, co-chair and other
members of the guideline panel.
2.3. Development of clinical question
A single key clinical question was developed according to the
P.I.C.O. acronym based on definition of population (P), intervention
(I), comparison (C) and outcomes (O).
The guideline panel unanimously agreed to address the
following clinical question:
Should oncoplastic breast-conserving surgery vs. standard
breast-conserving surgery be used for the treatment of operable
breast cancer in adult women who are suitable candidates for
breast conserving surgery?
2.4. Identification of outcomes
The guideline panel used the GRADEpro Guideline Development
Tool [17] to deliberate and then prioritize outcomes of interest.
The panel identified the following outcomes of benefit:
1. Quality of life
2. Patient’s satisfaction with aesthetic outcome
3. Loco-regional recurrence
4. Re-excision rate (defined as re-excision of positive margins)
5. Conversion to mastectomy (defined as mastectomy for pos-
itive margins)
6. Overall survival




11. Aesthetic outcome non-patient-reported
12. Insomnia
13. Fatigue
The following outcomes were judged as “critical” for decision-
making in oncoplastic breast surgery:
1. Quality of life
2. Patient’s satisfaction with aesthetic outcome
3. Loco-regional recurrence
4. Re-excision rate (defined as re-excision of positive margins)
5. Conversion to mastectomy (defined as mastectomy for positive
margins)276. Overall survival
7. Margin positivity rate
8. Disease-free survival
9. Depression
The panel identified the following adverse outcomes that
potentially cause harm to patients:
1. Surgical complications (defined as post-operative complication
presenting within one month after the surgical procedure).
2. Post-operative need for second level exams (defined as the need
of second level exams in the follow-up due to imaging abnor-
malities deriving from the surgical procedure)
3. Pain (defined as post-operative pain)
4. Time to adjuvant treatment (defined as time from the surgical
procedure to the start of any adjuvant therapy)
5. Return to operating theatre within 7 days (defined as any re-
intervention for early post-operative complication)
6. Operative time (defined as the duration of the surgical
procedure)
“Surgical complications” was the only outcome judged to be
“critical” for decision-making, with the other outcomes being
classified as “important”.
2.5. Search strategy and selection of evidence
A systematic literature review was performed by searching
PubMed, Embase and Cochrane Library, Psychinfo, and Lilacs (up to
July 19, 2020) without date or language restrictions. The full search
strategy is available as Supplemental File 2. Main articles were
cross-referenced to ensure that all relevant publications were
identified. The PRISMA flow-chart is reported in Supplemental file
3. Information relating to study design, patient characteristics,
treatment received, and study results were documented.
2.6. Certainty of evidence
For each selected outcome, an evaluation of the certainty of
evidence was performed based on the GRADE approach. GRADE
encompasses five main domains: study limitations, imprecision,
indirectness, inconsistency, and publication bias. Based on the
study design, the certainty level starts at a pre-specified level (high
certainty for randomized controlled trials). The detection of limi-
tations in one or more of the five domains can lead to downgrading
the certainty of evidence. The final judgment can be one of the
following: high, moderate, low and very low. A summary of the
certainty of evidence and a quantitative synthesis of effects for each
outcome are shown in an evidence profile table (Supplemental file
4).
2.7. Evidence to decision (EtD) framework
The EtD framework provides a transparent and structured
approach to support the decision-making process [12]. It allows
evidence to be summarized in relation to prioritization of the
problem, substantiality of desirable and undesirable effects, bal-
ance of the effects, certainty of evidence, patients values and
preference, use of resources, equity, acceptability and feasibility.
2.8. Benefit/harm balance and clinical recommendation
During the face-to-face meeting held in Milan (December 2019),
the panelists were asked to express their opinion on each of the
domains of the EtD (priority of the problem, substantiality of
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evidence, patients values and preferences, equity, acceptability and
feasibility).
At this point of the decision-making process, the panel voted on
the relative balance between benefits and harms for the interven-
tion (oncoplastic BCS) and its comparator (standard BCS) with the
options of 7 categories: favors the comparison, possibly favors the
comparison, does not favor either the comparison or the inter-
vention, possibly favors the intervention, favors the intervention,
varies, don’t know. In addition, the strength of the recommendation
was evaluated with the option of 5 judgments: strong recom-
mendation against the intervention, conditional recommendation
against the intervention, conditional recommendation for either
the comparison or the intervention, conditional recommendation
for the intervention, strong recommendation for the intervention.
The AGREE-reporting checklist was followed to guide the
reporting of the present recommendation [20].
3. Results
3.1. Search strategy results and details of the identified relevant
studies
The literature search yielded 18,699 items after elimination of
duplicate records. A total of 47 full-text articles were assessed for
eligibility, amongst which 37 studies met pre-defined criteria with
29 studies included in meta-analyses [21e50] (Fig. 1).
A comprehensive search strategywas applied and for each of the
other GRADE domains titles and abstracts were screened with the
aim of identifying potentially eligible articles. Full texts for the
latter were sought and results of systematic reviews in EtD are
reported herein (Supplemental file 5).
3.2. Prioritization of outcomes
The panel deemed the following outcomes to be critical (mean
value):
1. Quality of life (8.40)
2. Patient’s satisfaction with aesthetic outcome (8.14)Fig. 1. Forest Plot. M
283. Loco-regional recurrence (7.53)
4. Re-excision rate (7.50)
5. Conversion to mastectomy (7.50)
6. Overall survival (7.07)
7. Margin positivity rate (6.92)
8. Disease-free survival (6.80)
9. Depression (6.73)
10. Surgical Complications (6.71)3.3. Included studies
The analysis included studies conducted in the United States, the
United Kingdom, Europe, South America, China, India, Canada,
Israel and Iran with involvement of 193,833 patients in total and a
mean of 6683 women per trial.
All studies included patients with invasive carcinoma or ductal
carcinoma in situ (DCIS). These were managed with various tech-
niques of oncoplastic breast-conserving surgery (level I (excision of
less than 20% of breast volumewithout skin excision - parenchymal
rearrangements) and level II (excision of 20e50% of breast volume -
chest wall perforator flaps; therapeutic mammoplasties) [51] that
were compared with standard BCS (wide local excision, lumpec-
tomy, quadrantectomy).
Study design included prospective cohorts, case-control studies,
cross-sectional studies, and database analyses.
The main features of primary studies are summarized in Sup-
plemental file 6.
There were 7 studies [22,24,26,28,36,38,49] that included vari-
able proportions of patients (range 2.1%e28.9%) undergoing neo-
adjuvant systemic treatments before any surgical intervention.
3.4. Effects of intervention
All results were presented in the Summary of Findings
Table (Supplemental file 7).
3.4.1. Margin positivity
A total of 13 studies reported data on margin positivity rates
[22,24,25,28,30e33,35,38,40,42,49] and these were all designed asargin positivity.
N. Rocco, G. Catanuto, M. Cinquini et al. The Breast 57 (2021) 25e35observational studies. They included more than 2000 patients
having oncoplastic BCS and almost 3 times as many (5756) patients
with standard BCS. Positive margins were reported in 137/2197
(6.2%) patients in the oncoplastic BCS group and 607/5756 (10.5%)
patients in the standard BCS group.
The OR for margin positivity was 0.45 (95% C.I. 0.29 to 0.71; I-
squared 93%) in favor of oncoplastic surgery (Fig. 1), representing
an absolute reduction of 55 fewer cases of positive margins per
1000 patients (from fewer 72 fewer to 28 fewer) (certainty of
evidence ¼ low).
3.4.2. Re-excision of positive margins
Similarly, a total of 12 studies reported data on rates of re-
excision for positive margins rates
[22,23,28,30e32,34,40,42,43,48,49] and these were also observa-
tional studies. They included more than 8000 patients managed
with oncoplastic BCS and almost 100,000 (97585) patients treated
with standard BCS. This translates into an OR for margin re-excision
of 0.61 (95% C.I. 0.42 to 0.87) in favor of the oncoplastic BCS group
(Fig. 2), for which the absolute risk is 1 less case of re-excision per
1000 patients.
(level of certainty ¼ very low).
3.4.3. Conversion to mastectomy
Rates of conversion to mastectomy were reported in 8 studies,
all of which were observational [22,25,29e31,38,43,49].
These included a total of 665 patients who underwent onco-
plastic BCS and 1220 patients with standard BCS. Fewer than 10% of
patients in both the oncoplastic (48/665; 7.2%) and standard (94/
1220; 7.7%) groups required completion mastectomy for positive
margins.
The OR for conversion to mastectomy for positive margins was
0.82 (95% C.I. 0.42 to 1.58) showing a not significant difference
between the oncoplastic over standard BCS (Fig. 3). This represents
an absolute reduction in conversion to mastectomy of 13 cases per
1000 patients (from 43 fewer to 39 more). (level of certainty¼ very
low).
3.4.4. Loco-regional recurrence
Only 4 studies included data on loco-regional recurrence rates
[23,25,30,36] and once again were confined to all observationalFig. 2. Forest Plot
29studies. Collectively, these studies involved a total of 504 patients
who underwent an oncoplastic procedure and 723 patients treated
with standard BCS. After a follow up period ranging from 18 to 76
months, rates of loco-regional recurrence were 1.2% for the onco-
plastic BCS group (6/504) and 2.2% in the standard BCS group (16/
723).
The OR for loco-regional recurrence was 0.63 (95% C.I. 0.11 to
3.51) showing a not significant difference between the two groups
(Fig. 4). (level of certainty ¼ very low).
3.4.5. Disease-free survival
Disease-free survival data was available from 4 observational
studies [24,27,39,44]. These included a total of 1864 patients who
underwent oncoplastic BCS and 6256 patients treated with stan-
dard BCS. Any form of recurrence was documented in 10% of pa-
tients in the oncoplastic surgery group (187/1864) compared with
7.7% for standard BCS (482/6256). There was a broad range in
duration of follow-up from 41 months to 86 months. The HR for
recurrence was 1.15 (95% C.I. 0.96 to 1.37) (Fig. 5). This translates in
the absence of significant difference between the two groups for
this outcome. (level of certainty ¼ very low).
3.4.6. Overall survival
Overall survival datawas available in 7 observational studies but
these were observational and prone to confounding
[24,27,33,36,39,43,44].
These included a total of 2384 patients who underwent an
oncoplastic breast conserving surgery and 6833 patients with
standard BCS. The proportion of deaths in these 2 surgical groups
were similar: 5.3% (127/2384) for the oncoplastic group and 6.5%
(446/6833) for the standard BCS group. Follow-up ranged from 41
months to 86 months. The HR for death was 1.01 (95% C.I. 0.83 to
1.24) (Fig. 6). This translates in the absence of significant difference
between the two groups for this outcome (level of certainty ¼ very
low).
3.4.7. Quality of life
Information on quality of life (QoL) was available in 4 studies
each of which were observational in design [28,45,47,49]. However,
high levels of heterogeneity precluded any meaningful meta-
analysis and therefore these were reported narratively.. Re-excision.
Fig. 3. Forest Plot. Conversion to mastectomy.
Fig. 4. Forest Plot. Locoregional recurrence.
Fig. 5. Forest Plot. Disease-free survival.
Fig. 6. Forest Plot. Overall survival.
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domains for oncoplastic BCS patients at 12 months including
physical and psychological well-being, health perception, vitality,
role-, emotional-, and social functioning [49]. Furthermore, these
authors documented how much more positively patients viewed
the future and demonstrated better mental health and self-esteem
(assessed with the Short Form-36 and the Rosenberg-EPM Self-
Esteem Scale) [52,53]. Nonetheless, there was omission of data on
two out of the six QoL domains (body image and sexual
functioning).
Di Micco and colleagues found that psychological functioning
was not significantly worse in patients undergoing oncoplastic BCS
[28], whilst improved psychological and sexual well-being was
reported by Schechter and colleagues for oncoplastic patients [47].
Both these studies used the breast Q [54] tool and the latter authors
found no significant differences for other BREAST-Q domains
tested. Likewise Rose and colleagues reported significantly better
psychosocial well-being for patients undergoing oncoplastic
compared with standard BCS (OR 2.15; CI 1.25e3.69), with no dif-
ferences for the domains of physical and sexual well-being. (level of
certainty ¼ low) [45].
3.4.8. Patient’s satisfaction with aesthetic outcome
Data was provided on patient satisfaction with aesthetic
outcome in 7 studies all with an observational design
[21,28,41,42,46e48]. As for QoL, there were high levels of hetero-
geneity between these studies, and meta-analyses of data was not
possible on account of this. Acosta-Marin and colleagues assessed
patient-reported aesthetic outcome using a scale from 1 (bad) to 5
(excellent) [21]. The average cosmetic score at 6 months for the
oncoplastic BCS group was 4.4 compared with 4.2 for those having
standard BCS. The final mean cosmetic scores reported by patients
for these two groups at 12 months were 4.5 and 4.2 respectively.
Di Micco and colleagues evaluated patient-reported aesthetic
outcome using BREAST Q and reported a mean score of 68 and 80
for oncoplastic and standard BCS groups respectively [28].
Schechter and colleagues also used BREAST-Q to assess patient
reported aesthetic outcome and found mean scores of 75.18
(satisfaction with breast domain) for the oncoplastic group but a
rather lower score of 39.64 for the standard BCS group [47].
Interestingly, using a scale from 1 (excellent) to 4 (unsatisfac-
tory), Santos and colleagues reported a higher proportion of pa-
tients with excellent results in the standard group (69.2%) versus
61.4% in the oncoplastic group (total number of patients in each
group 45 and 35 respectively) [46].
In contrast to the above studies, Tenofsky and colleagues ac-
quired patient-reported aesthetic outcome data from the patient
charts without use of a validated breast questionnaire and reported
excellent results in 13.8% of patients having an oncoplastic pro-
cedure compared with only 7.1% for the standard BCS group [48].
Ojala and colleagues evaluated patient-reported aesthetic
outcome using the Breast Cancer Treatment Outcome Scale
(BCTOS) [55] and reported good outcomes in 61% of patients in the
oncoplastic BCS group and 81% in the standard BCS group
(p < 0.001) [41]. The mean BCTOS aesthetic score was worse after
oncoplastic (1.62) than standard (1.84) BCS (p ¼ 0.002). Moreover,
oncoplastic resection appears to score worse for almost every
aesthetics category using this instrument.
Plasdottir and colleagues employed a non-standardized scale to
assess patient-reported aesthetic outcomes by asking patients
directly whether they were happy with the appearance and shape
of their breast(s) following surgery [42]. There were high levels of
patient satisfaction rate with cosmetic outcomes for both surgical
groups, although a slightly higher proportion of women in the
oncoplastic group gave the responses “I agree very much” or “I31agree for most parts” (no statistically significant difference).
(level of certainty ¼ very low).
3.4.9. Depression
None of the studies included any data on post-operative
depressive illness following either type of BCS.
3.4.10. Surgical complications
There were 14 studies within this systematic review that re-
ported data on surgical complications
[21,23e26,28e32,34,36,42,47] and these involved a total of 10437
patients treated with oncoplastic BCS and 174053 patients treated
with standard BCS. The overall incidence of post-operative com-
plications was 595/10437 (5.7%) for patients in the oncoplastic
group and 4308/174053 (2.5%) for patients in the standard BCS
group. These included infection, seroma, hematoma, non-healing
wound, wound dehiscence, skin necrosis, pain, and abscess
formation.
The OR for surgical complications was 1.35 (95% C.I. 0.97 to 1.88)
(Fig. 7) representing a not significant. difference between the two
groups for this outcome (level of certainty ¼ very low).
3.5. Values and preference, equity, acceptability, feasibility
A summary of evidence levels and panelist’s judgments are
presented in EtD (Supplemental file 5).
3.6. Resource use and cost-effectiveness
Only one study on Complete Economic Evaluation (CEE) was
identified during this systematic review and indicated an overall
cost-effectiveness of large volume oncoplastic surgery when
compared to standard lumpectomy [59]. The cost-effectiveness
analysis is described in the attached document (Supplemental file
8).
Half the panelists (50%) considered the certainty of evidence for
resources to support use of oncoplastic surgery to be very low.
Although no studies compared resource requirements for the two
surgical approaches in terms of direct and indirect costs, three-
quarters (75%) of the panel considered these to be moderate,
with oncoplastic BCS not incurring larger increments in procedural
costs compared to standard BCS approaches. Nonetheless, it was
recognized that some level II procedures demand longer operative
times and correspondingly higher costs associated with theatre
staffing and occupancy.
Just over one-third (37.5%) of the panel considered the cost-
effectiveness of oncoplastic BCS probably favors whilst a quarter
(25%) stated that it definitely favors the intervention.
3.7. Recommendation
In the light of summarized judgments for each domain in EtD,
panelists were asked to comment on the recommendation for use
of oncoplastic BCS for treatment of operable breast cancer that is
suitable for breast conserving surgery.
Almost half (43%) of the panelists offered a conditional recom-
mendation, whilst just over one-third (36%) a strong recommen-
dation for the intervention (oncoplastic BCS). Notably one-fifth of
panelists (21%) expressed a conditional recommendation for either
the intervention or the comparator (standard BCS).
Based on this voting outcome, the following recommendation
emerged as a consensus statement: Oncoplastic breast conserving
surgery should be recommended versus standard breast
conserving surgery for the treatment of operable breast cancer in
adult women who are suitable candidates for breast conserving
Fig. 7. Forest Plot. Surgical complications.
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4. Discussion
The current evidence base for oncoplastic BCS derives mainly
from observational studies and single-center case-series with few
studies directly comparing oncoplastic to standard BCS in matched
cohorts of patients. Despite low levels of evidence for most studies,
there is an emergent theme that some of the more obvious and
anticipated benefits of oncoplastic BCS are not supported by the
evidence with this meta-analysis failing to yield odds ratios
significantly in favor of oncoplastic BCS. Moreover, critical out-
comes relating to QoL have not been investigated in the majority of
studies and available data is often based on assessment with non-
standardized scales or inappropriate use of standardized scales.
More than three-quarters (79%) of panelists offered a conditional or
strong recommendation in favor of adopting oncoplastic tech-
niques versus standard BCS for surgical management of adult
women with operable breast cancer who are otherwise suitable
candidates for breast conserving surgery (without any clear indi-
cation for mastectomy).
According to this systematic review of the literature, oncoplastic
BCS is associated with both a significant reduction in rates of pos-
itive margins (with a low certainty of evidence) and re-excision
(with a very low certainty of evidence) when compared to stan-
dard forms of BCS that generally involve resection of smaller vol-
umes of tissue.
However, other potentially desirable effects of oncoplastic BCS
are not apparent from results of this meta-analysis comparing the
two surgical approaches of oncoplastic with standard BCS.
This meta-analysis provides tentative support for the intuitive
assumption that rates of loco-regional recurrence are lower for
oncoplastic BCS that tends to be associated with wider margins of
resection. However, local recurrence is determined by multiple
factors including tumour size and oncoplastic procedures may be
biassed towards larger tumours. This benefit for oncoplastic versus
standard BCS was not significant with a very low level of certainty.
Patients undergoing oncoplastic BCS had slightly worse disease-
free and overall survival, although once again there was a very
low level of certainty for this outcome and hazard ratios were close32to unity.
This meta-analysis did not include the key parameters QoL and
patient-reported aesthetic outcomes as few studies contained data
on these outcomes and methods of assessment were highly
heterogeneous.
Notwithstanding these shortcomings, more than half (54%) of
panelists anticipated that the desirable effects would be favourably
affected by oncoplastic BCS.
Surgical complications were considered to be the only unde-
sirable effect of oncoplastic versus standard breast conserving ap-
proaches. Oncoplastic surgery was associated with a slight (non-
significant) increase in rates of complications but the certainty of
evidence was very low. Just over one-third of the panel expressed
the opinion that any undesirable anticipated effects were small.
A possible reason why more than three-quarters of panelists
offered a conditional or strong recommendation in favor of
adopting oncoplastic techniques versus standard BCS for surgical
management of adult women with operable breast cancer who are
otherwise suitable candidates for breast conserving surgery even
though no strong evidence was available in literature for most of
the highly prioritized outcomes is that they strongly relied on the
significant impact of oncoplastic techniques on the reduction of
positive margins and excision rates.
4.1. Limitations of the study
One of the limitations of the study relates to the composition of
the panel that include some surgeons who did not perform onco-
plastic procedures andmay therefore have been intrinsically biased
against this approach.
Not all panelists engaged in the feedback process, both in terms
of prioritization of outcomes phase and the pre-voting session.
Although all members of the panel considered oncoplastic BCS
to be a research priority, some breast cancer specialists are skep-
tical as to whether this needs formal evidence-based validation; it
could be viewed as simply a variant form of breast conserving
surgery that has already been validated in randomized controlled
trials [2,3].
Other limitations relate to a paucity of high quality publications
that either fail to address key outcomes or include poorly designed
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assessment of outcomes.
The panel prioritized outcomes in the preliminary phase of the
GRADE process and identified quality-of-life and patient-reported
aesthetic outcome as the two most relevant outcomes for onco-
plastic BCS, although ironically these outcomes were excluded from
most studies comparing oncoplastic and standard BCS. Only three
studies assessed QoL, with one of these using standard measure-
ment tools inappropriately by not applying all the domains.
Amongst those studies assessing patient-reported aesthetic
outcome, only half used standardized tools with others using non-
validated methods.
Complications have likewise often been assessed without use of
standardized tools with much variation in definition and assess-
ment of surgical complications across different studies. Currently
available tools for assessment of complications should be refined
and adapted.
Another limitation of this meta-analysis relates to recent
consensus on definition of a negative margin. A minimum margin
of clearance (no ink on tumor for invasive carcinoma and 2 mm for
DCIS) is now acceptable following wide excision of both invasive
and non-invasive disease [60,61]. Less stringent margin policies
have arguably detracted from the benefit of oncoplastic surgery in
terms of both rates of margin positivity and re-excision (although
rates of re-excision are very low in both cohorts). The apparent
adverse effect of oncoplastic surgery on disease-free and overall
survival, may reflect the poor quality of published studies to-date
with introduction of substantial bias and confounding variables
(no information is available on biology and stage of cancers in the
two cohorts of oncoplastic and standard surgery).
4.2. Subgroup considerations
Data available in the literature did not allow any subgroup
analysis for level I versus level II oncoplastic procedures. Similarly,
data could not be extracted on patients with locally advanced
breast cancer managed with primary systemic treatments prior to
either oncoplastic or standard BCS. Also it was not possible to
stratify results based on age categories (<40, 41e65, >65 years of
age).
4.3. Research priorities
The generation of robust evidence is challenging for surgery and
limited by standardization of techniques and tailored approaches to
treatment.
Paramount amongst the knowledge gaps in breast cancer
research and treatment is the need to carefully evaluate the effec-
tiveness of oncoplastic BCS which represents an escalation of sur-
gical complexity. There are areas of controversy to be resolved,
especially relating to complications, cost-effectiveness and patient
reported outcomes. The UK Association of Breast Surgery have
analyzed key research gaps [62], whilst a European consensus
conference revealed significant variation in several aspects of
oncoplastic practice [63]. The Oncoplastic Breast Consortium
(OPBC) [64] performed a structured study following a Delphi pro-
cess [65] with the aim of prioritizing knowledge gaps and defining
optimal methodological strategies to address these.
The OPBC consensus panel recommended a prospective multi-
center cohort study with propensity score matching and satisfac-
tionwith breast (assessed with BREAST-Q) as the primary endpoint
to address the impact of oncoplastic surgery on QoL. Similar study
design with alternative endpoints was also recommended for
evaluating complications, return to the operating room and delays
in commencement of adjuvant therapies.334.4. Monitoring and evaluation
Outcomes in breast oncoplastic surgery should be evaluated
using standard tools. Those currently available should be refined
and adapted.
4.5. Implementation considerations
Lack of access to well-structured training in oncoplastic breast
surgery was identified as a principal barrier to more widespread
adoption of these techniques across the world. Dedicated training
programs should be established by postgraduatemedical education
systems under the aegis of professional associations allied to breast
cancer management.
5. Conclusions
The GRADE systemwas employed to analyze published data and
seek support for oncoplastic BCS as the new “state of the art” sur-
gical approach to early stage breast cancer compared to standard
BCS. A panel of world-renowned breast specialists was convened to
evaluate evidence, express personal viewpoints and establish
recommendations.
This review has revealed a low level of evidence for most of the
important outcomes in oncoplastic surgery with lack of any ran-
domized data and absence of standard tools for evaluation of
clinical outcomes and especially patients’ values.
There is substantial uncertainty in the balance between bene-
ficial and adverse effects of oncoplastic versus standard BCS and no
formal assessment of patients’ values and preferences has been
performed. This may lead to surgical over-treatment in some cases
when patients are less interested in potential benefits in terms of
margin status and re-excision. Othersmay specifically wish to avoid
disruption of an otherwise normal contralateral breast.
The outcome rated as most important by the panelists in the
prioritization process was QoL that has been sparsely investigated
to-date; data on cosmetic outcomes is heterogeneous with
assessment based on either subjective or objective methodologies.
There is an urgent need for appropriate and validated tools that can
routinely be applied in daily practice.
Poor access to accredited training programs hampers more
widespread implementation of a comprehensive oncoplastic ser-
vice, although these techniques are unlikely to impact equity of
health systems.
Despite areas of controversy, about one-third (36%) of panel
members expressed a strong recommendation in support of
oncoplastic BCS. Presumably, this reflects a synthesis of views on
the relative complexity of these techniques, associated complica-
tions, impact on quality of life and costs. Patients should be
informed of the following recommendation before consenting to
oncoplastic procedures for breast conserving surgery:
“Oncoplastic Breast Conserving surgery should be recom-
mended versus standard breast conserving surgery for the
treatment of operable breast cancer in adult women who are
suitable candidates for breast conserving surgery (with very low
certainty of evidence)”.Authors’ contribution
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